Leary, A., Estévez-García, P., Sabatier, R., Ray-Coquard, I., Romeo, M., Barretina-Ginesta, P., . . . Oaknin, A. (2024). ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
Citación estilo ChicagoLeary, A., et al. ENDOLUNG Trial. A Phase 1/2 Study of the Akt/mTOR Inhibitor and Autophagy Inducer Ibrilatazar (ABTL0812) in Combination With Paclitaxel/carboplatin in Patients With Advanced/recurrent Endometrial Cancer. 2024.
Cita MLALeary, A., et al. ENDOLUNG Trial. A Phase 1/2 Study of the Akt/mTOR Inhibitor and Autophagy Inducer Ibrilatazar (ABTL0812) in Combination With Paclitaxel/carboplatin in Patients With Advanced/recurrent Endometrial Cancer. 2024.